sponsored
PatientsVille.com Logo

PatientsVille

Itraconazole Medical Research Studies

Up-to-date List of Itraconazole Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Itraconazole Medical Research Studies

Rank Status Study
1 Unknown  Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
Conditions: Hematological Diseases;   Allogeneic Stem Cell Transplantation
Intervention: Drug: Itraconazole
Outcome Measures: efficacy evaluation;   group difference evaluation
2 Not yet recruiting Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
Condition: Alzheimer's Disease
Interventions: Drug: Rilapladib 25 mg;   Drug: Rilapladib 250 mg;   Drug: Itraconazole
Outcome Measures: Maximum observed concentration (Cmax), time of occurrence of Cmax (Tmax), area under the concentration-time curve over the dosing interval (AUC(0-Tau)) of rilapladib parent compound after single and repeat dosing, in part A of the study.;   Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)), and terminal phase half-life (T1/2) of rilapladib after repeat dosing, in part A of the study;   Cmax, Tmax, AUC(0-tau), and area under the concentration-time curve from time zero (pre-dose) to time of last quantifiable concentration (AUC(0-t)) of SB-664601 and GSK1174379 after single and repeat dosing, in part A of the study;   AUC(0-infinity) and T1/2 of SB-664601 and GSK1174379 after repeat dosing, as data permit, in part A of the study.;   AUC(0 infinity), AUC(0 t), and Cmax of rilapladib alone and in the presence of Itraconazole in part B of the study.;   Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by adverse events (AEs), in part A of the study.;   Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by 12-lead electrocardiogram (ECG) parameters, in part A of the study.;   Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by measuring vital signs, in part A of the study.;   Safety and tolerability of repeat oral doses of rilapladib 250 mg assessed by laboratory tests, in part A of the study.;   Tmax and T1/2 of rilapladib alone and in the presence of Itraconazole, in part B of the study.;   AUC(0-infinity), AUC(0-t), Cmax, Tmax and T1/2 of rilapladib metabolites, SB-664601 and GSK1174379, alone and in the presence of Itraconazole, in part B of the study.;   Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with Itraconazole, assessed by AEs, in part B of the study.;   Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with Itraconazole, assessed using ECG parameters, in part B of the study.;   Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with Itraconazole, assessed as vital signs, in part B of the study.;   Safety and tolerability of single oral dose of rilapladib 25 mg when dosed alone and concomitantly with Itraconazole, assessed by laboratory tests, in part B of the study.
3 Not yet recruiting Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib
Condition: Healthy
Interventions: Drug: Palbociclib Alone;   Drug: Palbociclib plus Itraconazole
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2);   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F)
4 Recruiting Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
Condition: Healthy
Interventions: Drug: CE/BZA;   Drug: Itraconazole
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] for BZA, total estrone adjusted for baseline and total equilin.;   Maximum Observed Plasma Concentration (Cmax) for BZA, total estrone adjusted for baseline and total equilin.;   Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)] for unconjugated estrone, unconjugated estrone adjusted for baseline, total estrone, and unconjugated equilin.;   Maximum Observed Plasma Concentration (Cmax) for unconjugated estrone, unconjugated estrone adjusted for baseline, total estrone, and unconjugated equilin.;   Apparent Oral Clearance (CL/F) for all analytes.;   Time to Reach Maximum Observed Plasma Concentration (Tmax) for all analytes.;   Apparent Volume of Distribution (Vz/F) for all analytes.;   Terminal Phase Elimination Half-Life (t1/2) for all analytes.
5 Recruiting Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects
Condition: Healthy Volunteers
Interventions: Drug: Lu AE58054 30 mg;   Drug: Lu AE58054 30 mg + Itraconazole 200 mg;   Drug: Itraconazole
Outcome Measures: Area under the Lu AE58054 plasma concentration-time curve from time zero to 24 hours post-dose (AUC0-24);   Maximum observed concentration (Cmax) of Lu AE58054;   Plasma pharmacokinetics for Lu AE58054: AUC0-24, Cmax, time at which maximum observed plasma concentration occurred (tmax), apparent oral clearance (CL/F), half life (t½) and apparent volume of distribution Vz/F;   Plasma pharmacokinetics for relevant metabolites: AUC0-24, Cmax, tmax, t½ and metabolic ratio (MR);   Plasma pharmacokinetic parameters for Itraconazole: CTrough;   Adverse events;   Columbia Suicide Severity Rating Scale (C-SSRS) categorization based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions
6 Not yet recruiting Topical Itraconazole in the Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Itraconazole
Outcome Measures: Downregulation in Gli expression;   Incidence, timing, and severity of treatment adverse events
7 Recruiting Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
Conditions: Febrile Neutropenia;   Hematological Diseases
Interventions: Drug: Micafungin sodium;   Drug: Itraconazole
Outcome Measure: Responses to therapy
8 Recruiting A Phase II Study of Itraconazole in Biochemical Relapse
Condition: Prostate Cancer
Intervention: Drug: Itraconazole
Outcome Measures: Proportion of Patients Who Achieve Greater than 50% decline in Prostate Specific Antigen;   Determination of Median Time to PSA Progression;   Determination of Median Time to Clinical Progession;   Determination of Median Metastasis-Free Survival;   Determination of Mean Percent Change Compared with pre-treatment in PSA doubling time;   Maximum Grade Toxicities Observed during Treatment;   Determination of the mean steady-state trough level of serum
9 Not yet recruiting Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
Conditions: Advanced Non Small Cell Lung Cancer;   Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions: Procedure: Pharmacokinetic sampling;   Drug: AZD9291;   Drug: Itraconazole
Outcome Measures: Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration (Cmax);   Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to infinity (AUC);   Pharmacokinetics of AZD9291, AZ5104 and AZ7550 by assessment of tmax;   Pharmocokinetics of AZ5104 and AZ7550 by assessment of AUC;   Pharmacokinetics of Itraconazole by assessment of Cmax;   Assessment of the safety and tolerability of AZD9291;   Pharmacokinetics of AZD9291, AZ5104 and AZ7550 by assessment of AUC(0-t);   Pharmacokinetics of AZD9291, AZ5104 and AZ7550 by assessment of AUC(0-120);   Pharmacokinetics of AZD9291, AZ5104 and AZ7550 by assessment of AUC(0-216);   Pharmacokinetics of AZD9291, AZ5104 and AZ7550 by assessment of λz;   Pharmacokinetics of AZD9291, AZ5104 and AZ7550 by assessment of t½;   Pharmacokinetics of AZD9291 by assessment of CL/F;   Pharmacokinetics of AZD9291 by assessment of Vz/F;   Pharmocokinetics of AZ5104 and AZ7550 by assessment of Cmax;   Pharmocokinetics of AZ5104 and AZ7550 by assessment of MR ratios of AUC (or AUC(0-t));   Pharmocokinetics of AZ5104 and AZ7550 by assessment of MR ratios of Cmax;   Pharmacokinetics of Itraconazole by assessment of tmax;   Pharmacokinetics of Itraconazole by assessment of AUCtau
10 Not yet recruiting Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
Conditions: Healthy Volunteers;   Non-smokers
Interventions: Drug: Pracinostat;   Drug: Itraconazole;   Drug: Ciprofloxacin
Outcome Measures: Peak plasma concentration Cmax in healthy nonsmoking subjects given a single-dose of pracinostat;   Number of participants with Adverse Events as a measure of safety and tolerability of single-dose pracinostat when administered with Itraconazole or with ciprofloxacin in healthy nonsmoking adult subjects.;   Peak plasma PK concentration Area Under the Curve (AUC)AUC 0-t, AUC 0-inf in healthy nonsmoking subjects given a single dose of pracinostat
11 Recruiting A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects
Conditions: Healthy Volunteers;   Pharmacokinetics of ASP3700
Interventions: Drug: ASP3700;   Drug: Itraconazole;   Drug: Placebo
Outcome Measures: Safety as assessed by adverse events (Part 1);   Safety as assessed by vital signs (Part 1);   Safety as assessed by laboratory tests (Part 1);   Safety as assessed by electrocardiogram (ECG) measurements (Part 1);   Safety as assessed by Bond and Lader VAS (Part 1);   Safety as assessed by C-SSRS (Part 1);   Safety as assessed by ARCI-49 (Part 1);   Pharmacokinetic parameter of Itraconazole (plasma): Ctrough (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): AUCinf (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): AUCinf (%extrap) (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): AUClast (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): Cmax (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma):λz (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): MRT (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): tlag (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): tmax (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): t1/2 (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (plasma): Vz/F (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (urine): Aelast (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (urine): Aeinf (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (urine): Aelast% (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (urine): Aeinf% (Part 2);   Pharmacokinetic parameter of ASP3700 with and without Itraconazole (urine): CLR (Part 2);   Safety as assessed by orthostatic evaluation (or blood pressure change in orthostatic challenge test) (Part 1);   Composite of pharmacokinetics of ASP3700: AUCinf, AUCinf(%extrap), AUClast, Cmax, CL/F, λz, MRT, tlag, tmax, t½, Vz/F (plasma) (Part 1);   Title: Composite of pharmacokinetics of ASP3700: Aelast, Aeinf, Aelast%, Aeinf%, CLR (urine) (Part 1);   Safety as assessed by adverse events, vital signs, orthostatic evaluation, laboratory tests, ECG measurements, C-SSRS, Bond & Lader VAS, ARCI-49 (Part 2)
12 Not yet recruiting Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)
Conditions: Prostate Cancer;   Castration-resistant Prostate Cancer
Interventions: Drug: Itraconazole;   Drug: Orteronel
Outcome Measures: Maximum Tolerated Dose;   Grade and severity of adverse events
13 Recruiting Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: MLN4924;   Drug: Fluconazole;   Drug: Itraconazole;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Paclitaxel
Outcome Measures: Cmax: Maximum Observed Plasma Concentration for MLN4924 (Part A);   AUC(0-tlast): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN4924 (Part A);   AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN4924 (Part A);   Number of Participants With Treatment-Emergent Adverse Events (TEAEs);   Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings;   Body Weight Measurements (Part A);   Number of Participants With Potentially Clinically Significant Vital Sign Findings;   Clearance (CL) Pharmacokinetic Parameter (Part A);   Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN4924 (Part A);   Volume-Steady State (Vss) Pharmacokinetic Parameter (Part A);   Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for MLN4924 (Part A);   Blood to plasma (B/P) ratio for MLN4924 (Part A);   Measurement of Disease Response (Part B)
14 Recruiting Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects
Condition: Infections, Bacterial
Interventions: Drug: GSK2140944 capsule;   Drug: GSK2140944 tablet;   Drug: Itraconazole capsule
Outcome Measures: Part 1: Composite of PK parameters following GSK2140944 administration in fasted and fed state;   Part 2: Composite of PK parameters of GSK2140944 following repeat oral dosing of Itraconazole;   Part 3: Safety and tolerability of GSK2140944 as assessed by adverse events (AEs);   Part 3: Safety and tolerability of GSK2140944 as assessed by review of concomitant medications;   Part 3: Safety and tolerability of GSK2140944 by laboratory assessments;   Part 3: Safety and tolerability of GSK2140944 as assessed by 12-lead electrocardiograms (ECGs);   Part 3: Safety and tolerability of GSK2140944 as assessed by vital signs;   Part 1: Safety and tolerability of GSK2140944 as assessed by AEs;   Part 1: Safety and tolerability of GSK2140944 as assessed by review of concomitant medications;   Part 1: Safety and tolerability of GSK2140944 by laboratory assessments;   Part 1: Safety and tolerability of GSK2140944 as assessed by 12-lead ECGs;   Part 1: Safety and tolerability of GSK2140944 as assessed by vital signs;   Part 2: Safety and tolerability of GSK2140944 as assessed by AEs;   Part 2: Safety and tolerability of GSK2140944 by laboratory assessments;   Part 2: Safety and tolerability of GSK2140944 as assessed by 12-lead ECGs;   Part 2: Safety and tolerability of GSK2140944 as assessed by vital signs;   Part 3: Composite of PK parameters of GSK2140944 following repeat oral dosing of GSK2140944
15 Recruiting Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
Condition: Neoplasms
Interventions: Drug: volasertib;   Drug: Itraconazole
Outcome Measures: area under the plasma concentration-time curve over the time interval from zero to 336 hours (AUC0-tz);   maximum measured plasma concentration (Cmax);   area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-infinity);   number of patients with adverse events;   number of participants with significant abnormalities in electrocardiogram results;   occurance of significant changes from baseline laboratory measurements
16 Recruiting ATCF (Azole Therapy in Cystic Fibrosis)
Conditions: Cystic Fibrosis;   Aspergillus Infections
Intervention: Drug: Itraconazole/voriconazole
Outcome Measures: Change in percentage of patients with a negativisation of sputum cultures in 2 successive samples;   plasma concentrations of antifungal agents;   safety of AFs including measurement of hepatic transaminases;   number of courses of steroids and antibiotics recording;   quality of life;   laboratory test indicators;   safety profiles of the antifungal agents;   mycological failures;   number of adverse events recording
17 Recruiting A Randomized Phase II Study of SUBATM-Itraconazole in Patients With Untreated Squamous NSCLC.
Condition: Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Arm A;   Drug: Arm B
Outcome Measures: Objective response rates;   Tumor blood flow.;   Median time to progression;   Adverse effects;   Itraconazole exposure parameters;   Tumor necrosis
18 Recruiting Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
Condition: Allergic Bronchopulmonary Aspergillosis
Intervention: Drug: Glucocorticoids
Outcome Measures: Remission rates in the two groups at six weeks and three months;   Percentage decline in IgE levels at six weeks and three months;   Complete remission rates in the two groups;   Relapse rates in the two groups at six and 12 months after completion of treatment;   Treatment related adverse effects in the two groups
19 Recruiting Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation
Condition: Burns
Interventions: Procedure: Stable Isotope Infusion Study;   Procedure: Collection of blood and tissues;   Procedure: Radiology testing: Dual-energy X-ray absorptiometry (DEXA), K+ counter, ultrasound, MRI;   Drug: Humatrope;   Drug: Ketoconazole;   Drug: Oxandrolone;   Drug: Propranolol;   Drug: Oxandrolone and propranolol combined;   Drug: Humatrope and propranolol combined;   Drug: Placebo;   Behavioral: Exercise--Hospital supervised intensive exercise program;   Behavioral: Home exercise program
Outcome Measure: Outcome assessments will include measures of muscle wasting, weakness, immunosuppression chronic bone loss and decreased growth with increases in metabolic, hemodynamic, inflammatory and scarring responses.
20 Recruiting Treatment Method Research of Invasive Pulmonary Fungal Infection
Condition: IFI
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Itraconazole etiology and treatment.

A major focus of Itraconazole research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Itraconazole